FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137204964> ?p ?o ?g. }

• W3137204964 endingPage "S12" @default.
• W3137204964 startingPage "S12" @default.
• W3137204964 abstract "PurposeInhaled pulmonary vasodilators (iPVD) are commonly used to lower PVR to modify the risk of acute RV failure in durable LVAD implantation or orthotopic heart transplantation (OHT). While inhaled nitric oxide (iNO) is the iPVD gold standard, inhaled epoprostenol (Veletri®) has been introduced as a cost-conscious alternative without high-grade evidence. Thus, we conducted an investigation to primarily determine if inhaled epoprostenol is equivalent to iNO in the ability to modify acute RVF after advanced heart failure therapies.MethodsOur group has enrolled 232 patients (LVAD, N=100; OHT, N=132) in a triple-blinded (clinician, subject, statistician) randomized controlled trial conducted between May 2017-October 2020 (NCT03081052). Participants were grouped into strata according to key clinical prognostic features. Within each stratum, subjects were assigned either iNO or inhaled epoprostenol via 1:1 randomization. To assess equivalency between the two treatment arms for our primary outcome analysis, we will calculate absolute and relative risk estimates and corresponding confidence intervals (CI). If the CI do not contain the margin of difference (15%), then we will conclude there is sufficient evidence that the risk of the primary outcome in each treatment arm is similar. For each secondary outcome, we will construct univariable effect estimates and corresponding CI, which will allow for assessment of difference between treatment arms. In the case that patients have switched to the other treatment arm, we will perform an intent-to-treat (ITT) analysis without reclassifying treatment assignment. To verify ITT results, we will perform a per-protocol analysis.EndpointsPrimary.LVAD: Moderate or Severe RVF (defined by INTERMACS, up to 21-days after surgery); OHT: PGD-RV treated with RVAD or VA-ECMO, up to 30-days after surgery. Secondary. Duration of postoperative mechanical ventilation, iPVD duration/cost, ICU and hospital lengths-of-stay, postoperative acute kidney injury, and 30-day mortality. Inhaled pulmonary vasodilators (iPVD) are commonly used to lower PVR to modify the risk of acute RV failure in durable LVAD implantation or orthotopic heart transplantation (OHT). While inhaled nitric oxide (iNO) is the iPVD gold standard, inhaled epoprostenol (Veletri®) has been introduced as a cost-conscious alternative without high-grade evidence. Thus, we conducted an investigation to primarily determine if inhaled epoprostenol is equivalent to iNO in the ability to modify acute RVF after advanced heart failure therapies. Our group has enrolled 232 patients (LVAD, N=100; OHT, N=132) in a triple-blinded (clinician, subject, statistician) randomized controlled trial conducted between May 2017-October 2020 (NCT03081052). Participants were grouped into strata according to key clinical prognostic features. Within each stratum, subjects were assigned either iNO or inhaled epoprostenol via 1:1 randomization. To assess equivalency between the two treatment arms for our primary outcome analysis, we will calculate absolute and relative risk estimates and corresponding confidence intervals (CI). If the CI do not contain the margin of difference (15%), then we will conclude there is sufficient evidence that the risk of the primary outcome in each treatment arm is similar. For each secondary outcome, we will construct univariable effect estimates and corresponding CI, which will allow for assessment of difference between treatment arms. In the case that patients have switched to the other treatment arm, we will perform an intent-to-treat (ITT) analysis without reclassifying treatment assignment. To verify ITT results, we will perform a per-protocol analysis. Primary.LVAD: Moderate or Severe RVF (defined by INTERMACS, up to 21-days after surgery); OHT: PGD-RV treated with RVAD or VA-ECMO, up to 30-days after surgery. Secondary. Duration of postoperative mechanical ventilation, iPVD duration/cost, ICU and hospital lengths-of-stay, postoperative acute kidney injury, and 30-day mortality." @default.
• W3137204964 created "2021-03-29" @default.
• W3137204964 creator A5011770922 @default.
• W3137204964 creator A5014583603 @default.
• W3137204964 creator A5017283465 @default.
• W3137204964 creator A5022951863 @default.
• W3137204964 creator A5027784658 @default.
• W3137204964 creator A5037713323 @default.
• W3137204964 creator A5049745789 @default.
• W3137204964 creator A5053864173 @default.
• W3137204964 creator A5065883685 @default.
• W3137204964 creator A5070641975 @default.
• W3137204964 creator A5086326199 @default.
• W3137204964 date "2021-04-01" @default.
• W3137204964 modified "2023-10-02" @default.
• W3137204964 title "Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies" @default.
• W3137204964 doi "https://doi.org/10.1016/j.healun.2021.01.1766" @default.
• W3137204964 hasPublicationYear "2021" @default.
• W3137204964 type Work @default.
• W3137204964 sameAs 3137204964 @default.
• W3137204964 citedByCount "0" @default.
• W3137204964 crossrefType "journal-article" @default.
• W3137204964 hasAuthorship W3137204964A5011770922 @default.
• W3137204964 hasAuthorship W3137204964A5014583603 @default.
• W3137204964 hasAuthorship W3137204964A5017283465 @default.
• W3137204964 hasAuthorship W3137204964A5022951863 @default.
• W3137204964 hasAuthorship W3137204964A5027784658 @default.
• W3137204964 hasAuthorship W3137204964A5037713323 @default.
• W3137204964 hasAuthorship W3137204964A5049745789 @default.
• W3137204964 hasAuthorship W3137204964A5053864173 @default.
• W3137204964 hasAuthorship W3137204964A5065883685 @default.
• W3137204964 hasAuthorship W3137204964A5070641975 @default.
• W3137204964 hasAuthorship W3137204964A5086326199 @default.
• W3137204964 hasBestOaLocation W31372049641 @default.
• W3137204964 hasConcept C126322002 @default.
• W3137204964 hasConcept C164705383 @default.
• W3137204964 hasConcept C168563851 @default.
• W3137204964 hasConcept C204243189 @default.
• W3137204964 hasConcept C2778198053 @default.
• W3137204964 hasConcept C2778849806 @default.
• W3137204964 hasConcept C2780930700 @default.
• W3137204964 hasConcept C44249647 @default.
• W3137204964 hasConcept C71924100 @default.
• W3137204964 hasConcept C82789193 @default.
• W3137204964 hasConceptScore W3137204964C126322002 @default.
• W3137204964 hasConceptScore W3137204964C164705383 @default.
• W3137204964 hasConceptScore W3137204964C168563851 @default.
• W3137204964 hasConceptScore W3137204964C204243189 @default.
• W3137204964 hasConceptScore W3137204964C2778198053 @default.
• W3137204964 hasConceptScore W3137204964C2778849806 @default.
• W3137204964 hasConceptScore W3137204964C2780930700 @default.
• W3137204964 hasConceptScore W3137204964C44249647 @default.
• W3137204964 hasConceptScore W3137204964C71924100 @default.
• W3137204964 hasConceptScore W3137204964C82789193 @default.
• W3137204964 hasIssue "4" @default.
• W3137204964 hasLocation W31372049641 @default.
• W3137204964 hasOpenAccess W3137204964 @default.
• W3137204964 hasPrimaryLocation W31372049641 @default.
• W3137204964 hasRelatedWork W1984386442 @default.
• W3137204964 hasRelatedWork W2003563983 @default.
• W3137204964 hasRelatedWork W2088544186 @default.
• W3137204964 hasRelatedWork W2094278111 @default.
• W3137204964 hasRelatedWork W2125804349 @default.
• W3137204964 hasRelatedWork W2154572616 @default.
• W3137204964 hasRelatedWork W2235155022 @default.
• W3137204964 hasRelatedWork W2407717929 @default.
• W3137204964 hasRelatedWork W3030276453 @default.
• W3137204964 hasRelatedWork W3184446988 @default.
• W3137204964 hasVolume "40" @default.
• W3137204964 isParatext "false" @default.
• W3137204964 isRetracted "false" @default.
• W3137204964 magId "3137204964" @default.
• W3137204964 workType "article" @default.